President - Psychedelic Medicine Association
Chief Clinical Officer, Numinus; Board Member, Psychedelic Medicine Association
Dr. Reid Robison is a board-certified psychiatrist and Chief Clinical Officer at Numinus, and oversees the clinical services, including teaching and training in ketamine-assisted psychotherapy, for the company's clinics across the US and Canada. He has led over 200 clinical trials in neuropsychiatry, and previously served as coordinating investigator for the MAPS-sponsored MDMA-assisted psychotherapy study of eating disorders. He is currently principal investigator for a number of psychedelic medicine studies with psilocybin, LSD and DMT. As an early adopter and researcher of ketamine in psychiatry, Dr. Robison got his first grant to study ketamine in 2011, and around that time also led a pivotal IV ketamine study for treatment-resistant depression by Janssen. To date, Dr. Robison has guided thousands of ketamine therapy journeys and Spravato dosing sessions, and has worked in ayahuasca retreat settings abroad. Dr. Robison is also an adjunct professor at both the University of Utah and Brigham Young University and board chair of the Psychedelic Institute, focused on education and research.
Professor of Psychiatry, Temerty Faculty of Medicine, University of Toronto
Dr. Allan S Kaplan is currently Senior Clinician/Scientist at the Center for Addiction and Mental Health (CAMH), and Professor of Psychiatry in the Temerty Faculty of Medicine, University of Toronto. His research over the past 40 years has focused on innovative treatment approaches for eating disorders and on the neurobiology and genetics of anorexia and bulimia nervosa. He has published over 200 peer reviewed journal articles, two books, 60 book chapters and over 250 abstracts. He was the inaugural Chair-Holder of the Loretta Anne Rogers Chair in Eating Disorders at Toronto General Hospital, the first endowed Chair in Eating Disorders in the world. He was President of the Academy for Eating Disorders from 2001-2002, and President of the International Eating Disorder Research Society from 2005-2006. He has received federal grant support from the National Institute of Mental Health in the USA and the Canadian Institutes of Health Research in Canada. He has been a co-investigator on several multisite drug trials investigating drug treatments for anorexia nervosa.
He is currently VP for Clinical Development for Xpira Pharmaceuticals, a company at the forefront of new approaches to treatment for psychedelic medicine.
Founder & Medical Director at Soft Reboot Wellness
Dr. Sara brings deep expertise in integrative ketamine therapy practices. She studied and trained in cardiothoracic anesthesia at Harvard Medical School and Columbia University. Her personal experience with mental health inspired her shift in focus from operating room medicine to psychedelic healing. Sara has additional training in psychedelic-assisted therapy and integrative healing from the California Institute of Integral Studies, MAPS, The Ketamine Training Center, The Integrative Psychiatry Institute, and The Academy of Integrative Health & Medicine. She has set an intention to practice psychedelic medicine with ethics, integrity, and a commitment to her patients’ holistic wellness.
A significant portion of the population will struggle with an eating disorder in their lifetime, and clinicians know how difficult these conditions can be to effectively treat. Currently, the options include nutrition education, psychotherapy, and/or medication.
However, could psychedelic medicines be a more effective method of addressing eating disorders?
To discuss the possibilities, and what research is showing so far, we have guests who are currently using psychedelic medicines (namely ketamine) to treat eating disorders and who have participated in the research on psychedelics for eating disorders.
They helped educate us on:
…and much more!
As always, there was be ample time for audience Q & A, so make sure you watch till the end!
You can find the Psychedelic Medicine Association on Twitter, LinkedIn, and on Facebook.
There was a problem reporting this post.
Please confirm you want to block this member.
You will no longer be able to:
Please allow a few minutes for this process to complete.